Efficacy of Agomelatine 25–50 mg for the Treatment of Anxious Symptoms and Functional Impairment in Generalized Anxiety Disorder: A Meta-Analysis of Three Placebo-Controlled Studies

被引：4
作者：
Dan J. Stein
Jon-Paul Khoo
Françoise Picarel-Blanchot
Valérie Olivier
Michael Van Ameringen
机构：
[1] University of Cape Town and Groote Schuur Hospital,SAMRC Unit on Risk and Resilience in Mental Disorders, Department of Psychiatry and Neuroscience Institute
[2] Toowong Specialist Clinic,Department of Psychiatry and Behavioural Neuroscience
[3] Servier Affaires Médicales,undefined
[4] Institut de Recherches Internationales Servier (IRIS),undefined
[5] McMaster University—MacAnxiety Research Centre,undefined
来源：
Advances in Therapy | 2021年 / 38卷
关键词：
Agomelatine; Functioning; Generalized anxiety disorder; Impairment; Meta-analysis; Neurology; Placebo; Short-term;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1567 / 1583
页数：16
相关论文
共 196 条
[1]  
Hoffman DL(2008)Human and economic burden of generalized anxiety disorder Depress Anxiety 25 72-90
[2]  
Dukes EM(2011)The size and burden of mental disorders and other disorders of the brain in Europe 2010 Eur Neuropsychopharmacol 21 655-679
[3]  
Wittchen HU(2013)Comprehensive review of generalized anxiety disorder in primary care in Europe Curr Med Res Opin 29 355-367
[4]  
Wittchen HU(2014)The diagnosis of and treatment recommendations for anxiety disorders Dtsch Arztebl Int 111 473-480
[5]  
Jacobi F(2019)Pharmacotherapy of anxiety disorders in the 21st century: a call for novel approaches Gen Psychiatr 32 e100136-1012
[6]  
Rehm J(2017)Anxiety disorders Nat Rev Dis Primers 3 17024-2068
[7]  
Parmentier H(2019)Novel investigational therapeutics for generalized anxiety disorder (GAD) Expert Opin Investig Drugs 28 1003-642
[8]  
Garcia-Campayo J(2015)Clinical practice. Generalized anxiety disorder N Engl J Med 373 2059-964
[9]  
Prieto R(2010)Agomelatine, the first melatonergic antidepressant: discovery, characterization and development Nat Rev Drug Discov 9 628-3619
[10]  
Bandelow B(2003)The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine(2C) receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways J Pharmacol Exp Ther 306 954-458
12345678910